1-hexyloxy-1H-benzo[d]-1,2,3-triazole | 60455-01-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-hexyloxy-1H-benzo[d]-1,2,3-triazole
• 英文别名: 1-hexyloxy-1H-benzotriazole；1-Hexoxybenzotriazole
• CAS: 60455-01-8
• 化学式: C₁₂H₁₇N₃O
• 分子量: 219.286
• InChiKey: RYEIZFFBHPQJAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  溴己烷 、 1-羟基苯并三唑 在 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以67%的产率得到1-hexyloxy-1H-benzo[d]-1,2,3-triazole
  参考文献：
  名称：

  Synthesis and Evaluation of 1-hydroxybenzotriazole Derivatives: Dual Inhibitors of Carbonic Anhydrase II and Sodium Hydrogen Exchanger I

  摘要：

  缺血再灌注损伤是器官移植中移植物功能受损的原因，也与脑功能障碍、缺血性心脏病、全身炎症反应综合征、胃肠功能障碍和多器官功能障碍综合征有关。细胞内pH对于缺血再灌注损伤中的细胞存活至关重要。钠氢交换蛋白I和碳酸酐酶II在调节细胞内pH方面起着关键作用。在再灌注期间抑制钠氢交换蛋白I和碳酸酐酶II分别被发现可以缓解缺血再灌注损伤。为了在缺血再灌注损伤治疗中获得更好的潜在药物分子，尝试合成钠氢交换蛋白和碳酸酐酶的双重抑制剂。羟基苯并三唑被认为是这种双重活性的中心药效团，合成了12种衍生物。所有衍生物均经过测试，用于检测钠氢交换蛋白I和碳酸酐酶II的抑制活性。对甲磺酸酯衍生物（12）发现是最有效的衍生物，对碳酸酐酶II的IC50为158.7±8.4 μM，对钠氢交换蛋白I的IC50为31.07±1.06 μM。尽管其效力低于标准药物，但这是对碳酸酐酶II和钠氢交换蛋白的双重抑制剂的首次报道。

  DOI：

  10.2174/1570178617999201014164710

文献信息

• Design, Synthesis and Antidepressant and Anticonvulsant Effect of 1-Alkoxy-1H-Benzo[d]-1,2,3-Triazole Derivatives
  作者：Yu Sun、Qing-Hao Jin、Yan Han、Di Yu、Qiu-Ping Dai、Zhou-Jun Zheng

  DOI：10.2174/1570180813666160826113018

  日期：2017.1.26

  Background: 21 novel 1-alkoxy-1H-benzo[d]-1,2,3-triazole compounds were designed, prepared and evaluated for their antidepressant and anticonvulsant effects in mice. Method: Compound 19 significantly decreased immobility time in the FST without altering the locomotor activity in the open field test, and exhibited higher levels of efficacy than the reference standard fluoxetine. Compound 19 significantly increased 5-HT, NE and 5-HIAA levels in mice brain, implying that the antidepressant activity might be mediated by these neurotransmitters. In the seizure test, compound 19 also showed better anticonvulsant activity against MES, whereas had not shown neurotoxicity (300 mg/kg). Conclusion: Our data indicated that compound 19 could potentially be used as the antidepressant drug in patients with epilepsy.

  背景：设计、制备并评估了21种新型1-烷氧基-1H-苯并[d]-1,2,3-噻唑化合物在小鼠中的抗抑郁和抗惊厥效果。 方法：化合物19在强迫游泳试验（FST）中显著减少了动物的失动时间，而不改变开放场实验中的运动活动，其疗效高于参照标准药物氟西汀。化合物19显著提高了小鼠大脑中5-HT、NE和5-HIAA的水平，这表明其抗抑郁活性可能与这些神经递质有关。在癫痫测试中，化合物19在对抗MES方面也表现出更好的抗惊厥活性，同时没有显示出神经毒性（300 mg/kg）。 结论：我们的数据表明，化合物19可能作为抗抑郁药用于癫痫患者。
• Novel copper and copper alloy corrosion inhibitors
  申请人：CALGON CORPORATION

  公开号：EP0397450A1

  公开（公告）日：1990-11-14

  The use of alkoxybenzotriazoles to inhibit the corrosion of metallic surfaces in contact with an aqueous system. Systems and compositions containing alkoxybenzotriazole are also claimed.

  使用烷氧基苯并三唑抑制与水体系接触的金属表面的腐蚀。还要求含有烷氧基苯并三唑的体系和组合物。
• Alkoxybenzotriazole compositions and the use thereof as copper and copper alloy corrosion inhibitors
  申请人：Calgon Corporation

  公开号：EP0478247A2

  公开（公告）日：1992-04-01

  An alkoxybenzotriazole, in combination with mercaptobenzothiazole, tolyltriazole, benzotriazole, a substituted benzotriazole and/or 1-phenyl-5-mercaptotetrazole, is used to inhibit the corrosion of metallic surfaces, particularly copper surfaces, in contact with an aqueous system. Systems and compositions are also claimed.

  一种烷氧基苯并三唑与巯基苯并噻唑、甲苯三唑、苯并三唑、取代苯并三唑和/或 1-苯基-5-巯基四唑结合使用，可用于抑制与水体系接触的金属表面，特别是铜表面的腐蚀。本发明还要求得到系统和组合物。
• METHOD FOR THE MANUFACTURE AND USE OF A BIONIC HYDROGEL COMPOSITION FOR MEDICAL APPLICATIONS
  申请人：Qventis GmbH

  公开号：US20200179419A1

  公开（公告）日：2020-06-11

  The invention relates to a method for the stabilization of a polysaccharide (hyaluronic acid) with a biomolecule—amino acid—through crosslinking, to generate a bionic hydrogel based on physiological building blocks for applications in regenerative medicine. The designed biosimilar hydrogel is intended to be used in regenerative medicine for the purpose of regenerate, rejuvenate and/or restore the structure or function of impaired or damaged tissues, and to promote healing. The manufacture method is composed of a single step that includes mixing L-lysine and hyaluronic acid sodium salt in an aqueous saline solution with either EDC/NHS as coupling agent.
• US5217686A
  申请人：——

  公开号：US5217686A

  公开（公告）日：1993-06-08